- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06716463
Ei-invasiivisen hengitystuen epäonnistumisen ennustaminen non-invasiivisen valvonnan avulla ei-intuboiduilla potilailla, joilla on akuutti hypokseminen hengitysvajaus tai ekstubaatiohäiriö. PREVISION-tutkimus (PREVISION)
Non-invasiivisen hengitystuen epäonnistumisen ennustaminen non-invasiivisen valvonnan avulla ei-intuboiduilla potilailla, joilla on akuutti hypokseminen hengitysvajaus tai ekstubaatiohäiriö: PREVISION-tutkimus
The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).
The main question, it aims to answer is:
Does abnormal regional ventilation could predict HFNC or NIV failure?
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
This is a single-center, prospective, physiological study.
The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.
The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.
The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.
HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.
The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.
After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Ontario
-
Toronto, Ontario, Kanada, M5B 1W8
- St. Michael's Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.
Kuvaus
Inclusion Criteria:
- Age of ≥ 18 years
- Using NIV or HFNC anywhere in the hospital
Exclusion Criteria:
- Chronic CO2 retention
- Neuromuscular disorder
- Requiring home NIV (CPAP or BIPAP)
- Tracheostomy
- Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Difference in regional ventilation distribution (%)
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Diaphragm or parasternal intercostal muscle thickening fraction
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Rapid shallow breathing index (RSBI) in mL/breaths/min
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The intensive care respiratory distress observation scale (IC-RDOS)
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The work of breathing scale
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Self-report of dyspnea visual analog scale (D-VAS)
Aikaikkuna: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- Unity Health Toronto
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .